Acquisition of UK Independent Clinical Research Organisation BIBRA International
Surrey Clinical Research is pleased to announce the acquisition of the clinical research and molecular sciences business units of BIBRA International Limited of Carshalton, Surrey.
A new investor group, led by Alan Wheatley, completed the acquisition on 10th May 2005. Mr Wheatley is the Chairman of Utilico Investment Trust PLC and Vice-Chairman of Carlton Corporate Finance Limited, and formerly the Senior Partner of Price Waterhouse, London, Chairman of 3i PLC and a director of a number of UK Boards including Cable & Wireless, British Steel, Legal & General, NM Rothchild’s Bank and Forte. Mr Wheatley will be joining the Board of Surrey Clinical Research as Chairman. In particular, the investor group has vast experience in the management of growing businesses with a specific competence in bringing private companies to the public market.
The Investor Group is working in partnership with the existing management of the two business units. The management team is led by Mr Steve Martin MRPharmS as Managing Director and Dr Chris Mugglestone as Medical Director, both of whom have significant experience in the technical and management of pharmaceutical development and clinical programs. Professor Brian Lake and Dr Clive Meredith who are in charge of the Molecular Sciences division are industry leaders in their fields of molecular science with specific reference to drug metabolism.
The Clinical Research unit is a specialist CRO in Phase I and early Phase II studies operating to international GCP and EU Directive regulations. It has a particular interest in the therapeutic areas of dermatology, osteoporosis, cardiovascular, oncology, hormones, nutrition and vaccines with GTAC accredited studies. SCR also has extensive experience in dental, smoking cessation, nutrition and micronutrient studies.
The Molecular Sciences unit is a specialist supplier of analytical services to the pharmaceutical industry. The unit operates to full GLP regulations and incorporates a full immunology service and expertise in genetics and pharmacogenomics.
Based in South London SCR has a large database of volunteers of differing age groups along with a wide recruitment area for volunteers and patients. SCR has a strategic alliance with St Anthony’s Hospital, one of the largest private hospitals in the South East England region with a specific competence in cardiovascular surgery. The combination of experience, facilities and collaboration with St. Anthony’s hospital provides an important centre for drug and nutritional development studies.
On the acquisition of the businesses by the Wheatley Investor Group, Mr Martin states “The investment and long-term future involvement in the business by our new partners has been warmly welcomed by all of the management and staff. Their vast commercial and senior management experience strongly complements that of the existing management and staff of the two SCR business units. The management believes that having such combined strength will ensure that the restructured business will become an unrivalled service provider to our customers within the pharmaceutical and nutrition industries”
The transaction and investment has been co-ordinated and overseen by the law firm Wellers of Bromley, Kent.
- Contact Information
- Steve Martin
- Managing Director
- Surrey Clinical Research
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.